Drug Trial Radar · NCT05262023
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
85
Actual
Start
Feb 1, 2022
Primary completion
Dec 2026
Study completion Nov 2028
Sponsor
- Lead sponsor
- Denali Therapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Takeda
- First posted
- Mar 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period. Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and PD of multiple doses of DNL593 in participants with frontotemporal dementia (FTD) over 25 weeks. Part B will be followed by Part C, an optional 18-month OLE period available for all participants who complete Part B.
Conditions
- Frontotemporal Dementia
Interventions
DNL593Drug
Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
PlaceboDrug
Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)Time frame: up to 18 months
- Incidence of treatment-emergent clinically significant abnormalities in safety laboratory valuesTime frame: up to 18 months
- Change from baseline in vital sign measurements: systolic and diastolic blood pressureTime frame: up to 18 months
- Change from baseline in vital sign measurements: heart rateTime frame: up to 18 months
- Change from baseline in vital sign measurements: respiratory rateTime frame: up to 18 months
- Change from baseline in vital sign measurements: body temperatureTime frame: up to 18 months
- Change from baseline in electrocardiogram (ECG) results including PR, QRS, and QTcF intervalsTime frame: up to 18 months
- Incidence of treatment-emergent clinically significant abnormalities in physical/neurological examination findingsTime frame: up to 18 months
- Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS; Parts B and C only)Time frame: up to 18 months
Locations
26 sites in 12 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
John Hopkins University
Baltimore, Maryland
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
University of Antwerp
Antwerp, Belgium
UZ Leuven
Leuven, Belgium
L2IP - Instituto de Pesquisas Clinicas LTDA
Brasília, Brazil
Faculdade de Medicina Da Universidade de São Paulo
São Paulo, Brazil
Hospital Universitario San Ignacio
Bogotá, Colombia
Grupo de Neurosicencias de la Universidad de Antioquia
Medellín, Colombia
Fakultni nemocnice v Motole
Prague, Czechia
CHU de Nantes
Nantes, France
CHU Rouen
Rouen, France
CHU Toulouse
Toulouse, France
ASST degli Spedali Civili di Brescia
Brescia, Italy
Azienda Ospedaliera Universitaria Careggi
Florence, Italy
IRCCS Istituto Auxologico Italiano
Milan, Italy
Azienda Ospedaliera Cardinale G Panico
Tricase, Italy
Erasmus University Medical Center
Rotterdam, Netherlands
Hospital de Braga
Braga, Portugal
Campus Neurológico Sénior
Torres Vedras, Portugal
Hospital Clinic de Barcelona
Barcelona, Barcelona, Spain
Hospital Universitario de Donostia
Donostia / San Sebastian, Guipúzcoa, Spain
Hospital Universitario Virgen del Rocio
Seville, Sevilla, Spain
Istanbul University Istanbul Medical Faculty
Istanbul, Turkey (Türkiye)
Ondokuz Mayis University Hospital
Samsun, Turkey (Türkiye)
Simbec Orion
Merthyr Tydfil, Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.